Welcome to our dedicated page for Fulgent Genetics SEC filings (Ticker: FLGT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Fulgent Genetics, Inc. filings document operating results, business updates, governance matters, capital-structure activity, and clinical disclosures for a company with laboratory services and therapeutic development operations. Form 8-K reports furnish earnings releases, investor presentation updates, stock repurchase activity, and material-event disclosures tied to the company's business and pipeline.
The company's proxy materials cover board and shareholder voting matters, executive compensation, equity awards, and other governance disclosures. Clinical and regulatory filings include updates related to FID-007 in recurrent or metastatic head and neck squamous cell carcinoma, while broader disclosures address financial performance, risk, and capital allocation.
Fulgent Genetics, Inc. CFO and Treasurer Paul Kim reported a routine tax-related share disposition. On April 26, 2026, 2,747 shares of common stock were withheld to satisfy tax withholding obligations arising from the vesting of previously assumed restricted stock units under a prior merger agreement. Following this withholding, Kim directly holds 365,800 shares of Fulgent common stock, indicating he retained a substantial equity position and did not report an open-market sale in this filing.
Fulgent Genetics, Inc. director and CEO Ming Hsieh, through The Ming Hsieh Trust, unwound a prepaid variable forward arrangement involving 750,000 shares of common stock. The trust had previously entered this forward contract with an unaffiliated bank in August 2023.
On March 9, 2026, the Hsieh Trust elected to cancel the agreement for all 750,000 shares and paid an aggregate of $10,708,875 to the bank. After this payment and cancellation, those 750,000 shares held by the trust are no longer pledged to the bank.
Following the reported positions, Ming Hsieh holds 900,634 shares directly and has additional indirect holdings, including 7,895,115 and 220,816 shares held by trusts, plus smaller positions of 1,000 shares each in a minor’s account and by an immediate family member.
Ming Hsieh, Chief Executive Officer and Chair of Fulgent Genetics, Inc., reports beneficial ownership of 8,867,303 shares of common stock, representing 30.74% of the 28,844,618 shares outstanding as of March 27, 2026. This includes 7,895,115 shares held by The Ming Hsieh Trust, which alone represents 27.37% of the company’s common stock.
Since the prior amendment, Hsieh’s position changed mainly through the vesting of multiple restricted stock unit awards and performance-based RSUs, with a portion of shares sold or withheld to cover tax obligations. The Trust also terminated two pre-paid forward arrangements covering a total of 1,550,000 shares. A large block of Trust shares remains pledged as security under a pre-paid forward arrangement and as collateral for a credit facility, and Hsieh shares voting and dispositive power over additional shares held by a Dynasty Trust and an immediate family member.
Fulgent Genetics, Inc. is asking stockholders to vote at its 2026 Annual Meeting on May 14, 2026 at 9:00 a.m. Pacific Time in El Monte, California. Investors will elect four directors for one-year terms, ratify Deloitte & Touche LLP as auditor for 2026, cast an advisory vote on named executive officer pay, and vote on the new 2026 Equity Incentive Plan. The proxy details ownership levels, with directors and executive officers as a group holding a significant stake, outlines board committee structure and independence, and explains the company’s pay-for-performance philosophy, risk controls, and cybersecurity and sustainability oversight.
Fulgent Genetics completed two related transactions to expand its pathology footprint. Its Inform Diagnostics subsidiary closed a Purchase and Sale Agreement to acquire all equity of dermatopathology lab StrataDx for approximately $13.5 million in cash, subject to post-closing adjustments. It also closed an Asset Purchase Agreement to buy substantially all assets and certain liabilities of Bako Diagnostics for approximately $43.4 million in cash. A joint press release cites a combined purchase price of about $56.9 million for the Bako and StrataDx acquisitions. In connection with the asset deal, Fulgent assumed a lease for roughly 29,099 square feet of lab and office space in Alpharetta, Georgia, running through July 31, 2032, with base rent of $15.54 per square foot from August 1, 2025 and 2% annual increases, plus operating expenses. Required acquired-business financial statements and pro forma financial information will be provided by amendment.
Fulgent Genetics, Inc. director and CEO Ming Hsieh, a more than ten percent owner, restructured a prior derivative arrangement tied to company stock. A trust associated with him had entered a prepaid variable forward contract in 2023 covering up to 750,000 shares of common stock.
On March 9, 2026, The Ming Hsieh Trust cancelled this agreement for all 750,000 shares and paid the counterparty an aggregate of $10,708,875. After this payment, those 750,000 shares are no longer pledged to the bank and remain held by entities associated with Hsieh.
Following these actions, Hsieh holds 900,634 common shares directly, and additional common shares indirectly, including 7,895,115 by trust, 220,816 by trust, 1,000 in a Uniform Transfers to Minors Act account, and 1,000 held by an immediate family member.
Fulgent Genetics President and COO Jian Xie reported several tax-related share withholdings of company common stock. On February 26, 2026, 1,140 shares were disposed of at $24.7600 per share to cover tax obligations from vesting restricted stock units. On March 1, 2026, additional tax-withholding dispositions of 1,079 and 8,147 shares occurred at $15.3300 per share. After these transactions, his direct holdings were reported as 375,313 shares of common stock. Separately, 220,816 shares are held indirectly by The Hsieh Family Dynasty Trust, for which Mr. Xie serves on the investment committee and disclaims beneficial interest except for any pecuniary interest.
Fulgent Genetics, Inc. CFO and Treasurer Paul Kim reported several tax-withholding dispositions of common stock tied to previously granted restricted stock units. On February 26 and March 1, 2026, shares were withheld at prices of $24.76 and $15.33 to cover associated tax obligations rather than open-market sales.
Fulgent Genetics Chief Scientific Officer Hanlin Gao reported tax-withholding share dispositions related to restricted stock unit vesting. On February 26, 2026 and March 1, 2026, several small blocks of common stock were withheld at prices of $24.76 and $15.33 per share to cover tax obligations, leaving Gao with direct ownership of just under 1.0 million shares after these administrative transactions.